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We would like to thank Dr. Gandjour [1] for his helpful comments
on our article [2]. Dr. Gandjour suggests that an intervention that
is clinically noninferior but leads to higher costs should not be
considered noninferior from an economic viewpoint. His con-
clusion is that the noninferiority margin for costs should be zero.
In our reply, we follow up on Dr. Gandjour’s example where
all bootstrap replications fall between -0.03 and 0 quality-
adjusted life-years (QALYs) as well as between 0 and 500 euro.
Dr. Gandjour argues that we should not consider an intervention
with costs below this margin economically noninferior because in
a high-prevalent disease such as minor depression, population
costs may easily add up to millions of euros. We agree with Dr.
Gandjour on this point. The same argument, however, can be
made for clinical effectiveness. In the case of the example (all
bootstrap estimates between -0.03 and 0 QALYs), the interven-
tion would be considered clinically noninferior according to the
“rules” of noninferiority research (lower limit of the 95% con-
ﬁdence interval is larger than the negative noninferiority margin).
Nevertheless, if such a situation arises, it is unlikely that we
would really consider the intervention clinically noninferior to
the control intervention because we are reasonably sure that
patients will be worse off with this new intervention than with
the control intervention. From a societal perspective, a small
difference in clinical outcomes may also be important in a high-
prevalent disease.
The methods described in our article aim to provide a deci-
sion framework that applies to situations where there are a priori
reasonable arguments to assume that the investigated interven-
tions are clinically and/or economically equivalent or noninferior.
Power calculations are then based on the margin for equivalence
or noninferiority, which is generally smaller than the clinically
relevant difference deﬁned in superiority trials. Statistical power
will normally be insufﬁcient to ﬁnd a result as precise as in the
example earlier. If such a situation arises, however, then one can
always base the ﬁnal conclusions on the fact that the new inter-
vention is clinically and economically inferior, and associated
with statistically signiﬁcantly lower effects and higher costs in
comparison with the control intervention. We assume that this
will hardly ever be the case in studies that were designed and
conducted under the assumption that effects and costs would be
equivalent or noninferior.—Judith E. Bosmans, PhD, Maurits W.
van Tulder, PhD, Health Technology Assessment Unit, Institute
for Research in Extramural Medicine, VU University Medical
Center, and Institute for Health Sciences, Faculty of Earth and
Life Sciences, Vrije Universiteit, Amsterdam, The Netherlands;
Martine C. de Bruijne, PhD, MD, Health Technology Assessment
Unit, Institute for Research in Extramural Medicine, VU Univer-
sity Medical Center, Amsterdam, The Netherlands; Hein P. J. van
Hout, PhD, Marleen L. M. Hermens, PhD, Department of
General Practice, Institute for Research in Extramural Medicine,
VU University Medical Center, Amsterdam, The Netherlands;
and Herman J. Adèr, PhD, Department of Clinical Epidemiology
and Biostatistics, VU University Medical Center, Amsterdam,
The Netherlands.
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